128 related articles for article (PubMed ID: 369693)
1. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
2. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
[TBL] [Abstract][Full Text] [Related]
3. [Use of preparation VM 26 (epipodophyllotoxin) for treating lymphomas in children and adults].
Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vialushkin VIa
Vopr Onkol; 1981; 27(4):82-7. PubMed ID: 7015693
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposide (VM-26).
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1982 May; 66(5):1121-5. PubMed ID: 7044533
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
6. Combination chemotherapy with VM-26, adriamycin bleomycin, and prednisone as a secondary treatment of malignant lymphoma.
Goldhirsch A; Pirovino M; Sonntag RW; Tschopp L; Ryssel HJ; Brunner KW
Cancer Treat Rep; 1980; 64(2-3):335-7. PubMed ID: 6157468
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
Rosenthal S; Harris DT; Horton J; Glick JH
Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of VP-16-213 in malignant lymphoma and melanoma.
Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW
Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
12. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
[TBL] [Abstract][Full Text] [Related]
14. [Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
Laurens A; Thevenot J; Charron D; Jorry F; Dumonchel P; Martola R
Ann Med Interne (Paris); 1977 May; 128(5):493-6. PubMed ID: 334012
[No Abstract] [Full Text] [Related]
15. Comparison of the use of teniposide and vincristine in combination chemotherapy for non-Hodgkin's lymphoma.
Cancer Treat Rep; 1982 Jan; 66(1):49-55. PubMed ID: 7053265
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
Qazi R; Elson P; Khandekar JD
Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
[No Abstract] [Full Text] [Related]
17. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.
Omura GA; Broun GO; Papps J; Birch R
Cancer Treat Rep; 1981; 65(11-12):1027-9. PubMed ID: 6794907
[TBL] [Abstract][Full Text] [Related]
18. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
[TBL] [Abstract][Full Text] [Related]
20. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]